Brief: Puma Biotechnology Announces Initiation of ALISCA-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
20/11/2024 13:58
Nov 20 (Reuters) - Puma Biotechnology Inc PBYI.O :
* PUMA BIOTECHNOLOGY ANNOUNCES INITIATION OF ALISCA™-BREAST1
PHASE
II TRIAL OF ALISERTIB IN HORMONE RECEPTOR-POSITIVE,
HER2-NEGATIVE METASTATIC BREAST CANCER
Source text: ID:nBw4CrjN9a
Further company coverage: PBYI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Puma Biotechnology
See all newsBrief: Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(C)(4)
Brief: Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)
Puma Biotechnology Inc reports results for the quarter ended June 30 - Earnings Summary
Corrected: Puma Biotechnology lifts 2026 outlook as Q2 revenue rises on NERLYNX demand
Brief: Puma Biotechnology Q2 Adjusted EPS USD 0.2